Figure 2.
Prediction of 6-month NRM during first month of GVHD therapy. AUCs of ROC curves (±95% CI) for MAPs (red circle), clinical responses (green circle), and a new algorithm combining biomarkers and clinical responses (blue circle) after 1, 2, and 4 weeks of treatment of GVHD. Patients with both clinical responses and biomarker values were included at each timepoint (week 1: n = 321; week 2: n = 323; week 4: n = 367). The difference between MAP and clinical responses alone was P < .0001 at all time points. The AUC of MAPs at week 1 (0.81) is significantly greater than that of clinical response at week 4 (0.70) (P = .0029).

Prediction of 6-month NRM during first month of GVHD therapy. AUCs of ROC curves (±95% CI) for MAPs (red circle), clinical responses (green circle), and a new algorithm combining biomarkers and clinical responses (blue circle) after 1, 2, and 4 weeks of treatment of GVHD. Patients with both clinical responses and biomarker values were included at each timepoint (week 1: n = 321; week 2: n = 323; week 4: n = 367). The difference between MAP and clinical responses alone was P < .0001 at all time points. The AUC of MAPs at week 1 (0.81) is significantly greater than that of clinical response at week 4 (0.70) (P = .0029).

Close Modal

or Create an Account

Close Modal
Close Modal